Author + information
- Robert Sancheza,b,
- Khurram Nasira,b,
- Alexa Klimchaka,b,
- Andreas Kuznika,b,
- Florence Joulaina,b and
- Andrew Briggsa,b
Background: Association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) events is well established. We aim to model one-year benefits of additional LDL-C lowering with alirocumab on CV risk.
Methods: Data from MarketScan was used to estimate baseline CV risk and lipid lowering therapy (LLT) use in patients with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia (HeFH) with baseline LDL-C ≥70 mg/dL. The sample was scaled to the US via an adjusted extrapolation method that accounted for differential weights by clinical and demographic profiles. The following hierarchically ranked conditions were included: HeFH secondary prevention, acute coronary syndrome (ACS) within 12 months of index, ischemic stroke, myocardial infarction > 12 months, other coronary heart disease, peripheral artery disease and HeFH primary prevention. Outcomes of interest included: hospitalization for ACS, coronary revascularization, ischemic stroke, CV death. We used a ∼52% reduction in LDL-C with alirocumab vs placebo and the log-linear relationship between LDL-C and CV events per Cholesterol Treatment Trialists.
Results: We included 33,526 patients representing 8.4 million US adults (mean age 66 years, 59% male, 37% with diabetes). Before and after alirocumab results can be seen in Table 1.
Conclusion: In a high CV risk population on background LLT above goal, further LDL-C lowering with alirocumab has considerable potential in lowering CV risk.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1126-326
- 2017 American College of Cardiology Foundation